Graft-versus-leukemia for AKR spontaneous leukemia-lymphoma.
Adoptive immunotherapy in the form of a transient graft of mismatched DBA/2 BM + LN cells was used in combination with several chemoradiotherapy regimens to treat AKR mice bearing advanced SLL. Leukemic mice treated in this manner had a significant prolongation of their MST and significantly higher survival rates 60 and 90 days posttreatment than corresponding control groups. Syngeneic- or allogeneic-matched cells did not provide substantial GVL effect. An inverse relationship that influenced survival was observed between the radiation dose and the dose of GVL effector cells used to treat leukemic AKR mice in the treatment model. Recurrence leukemia remains a major problem.
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D006087:Graft vs Host Reaction; D007942:Leukemia, Experimental / Q000276:immunology* / Q000401:mortality; D008198:Lymph Nodes / Q000637:transplantation; D007959:Lymphocyte Culture Test, Mixed; D008223:Lymphoma / Q000276:immunology* / Q000401:mortality; D051379:Mice; D008806:Mice, Inbred AKR; D008811:Mice, Inbred DBA; D009603:Nitroso Compounds / Q000627:therapeutic use; D011828:Radiation Chimera; D013997:Time Factors; D014184:Transplantation, Homologous
D009603:Nitroso Compounds; D000666:Amphotericin B; D003520:Cyclophosphamide